Clinical Research Directory

Inclusion Criteria: * Written informed consent and willingness to comply with protocol procedures. * Age \>= 18 years at the time of consent. * Histologically confirmed unresectable or metastatic clear cell RCC, or RCC with a clear-cell component, with radiographic progression after standard therapy. * Prior exposure to at least one PD-1 / PD-L1-based regimen and at least one VEGF-pathway targeted regimen, or documented intolerance / unsuitability for available standard systemic options. * At least one measurable lesion by RECIST 1.1. * Available archival tumor tissue or willingness to undergo fresh biopsy for central biomarker testing; protocoldefined tumor positivity for CD70 and/or CAIX is required. Dual-positive cases are preferred for the biomarkerexpansion portion. * ECOG performance status 0-1. * Adequate marrow, liver, cardiac, pulmonary, and renal function as defined by the protocol (for example, ANC, platelets, bilirubin, AST/ALT, creatinine clearance, oxygen saturation, and left ventricular function within protocoldefined limits). * Life expectancy of at least 12 weeks. * Negative pregnancy test for participants of childbearing potential and agreement to highly effective contraception during protocol-defined risk windows. * Previously treated brain metastases are allowed if clinically stable and off escalating corticosteroids for at least 14 days before lymphodepletion. Exclusion Criteria: * Active, untreated, or symptomatic central nervous system metastases, leptomeningeal disease, or uncontrolled seizure disorder. * Prior gene-modified cellular therapy (including prior CAR-T, CAR-NK, CAR-NKT, or TCR-engineered therapy) within the protocol-defined washout window. * Prior allogeneic stem cell transplant or solid organ transplant with ongoing clinically significant immunosuppression. * Active autoimmune disease requiring systemic immunosuppressive treatment; physiologic replacement doses are permitted. * Active uncontrolled infection, including uncontrolled hepatitis B, hepatitis C, HIV, tuberculosis, or sepsis. * Clinically significant hepatobiliary disease that could increase risk from CAIX-directed therapy, such as active cholangitis, primary sclerosing cholangitis, biliary obstruction, Child-Pugh B/C cirrhosis, or prior hepatic venoocclusive disease. * Clinically significant cardiovascular disease (for example, unstable angina, recent myocardial infarction, uncontrolled arrhythmia, or clinically meaningful heart failure). * Systemic corticosteroid use greater than 10 mg prednisone equivalent daily within 7 days before lymphodepletion, unless required as physiologic replacement. * Pregnancy or breastfeeding. * Another active invasive malignancy requiring systemic treatment, except for protocol-defined low-risk exceptions. * Known hypersensitivity to fludarabine, cyclophosphamide, or a critical study-product excipient.